Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Predicting early treatment termination in opioid use disorder: a machine learning model for risk stratification.

Created on 21 Nov 2026

Authors

Marta Narváez-Camargo, Cinta Mancheño-Velasco, Oscar Lozano-Rojas, Francisco A Márquez, Antonio Moreno-Moreno

Published in

The American journal of drug and alcohol abuse. Pages 1-14. Nov 20, 2026. Epub Nov 20, 2026.

Abstract

Background: Half of patients with opioid use disorder (OUD) discontinue opioid agonist treatment within the first year. Identifying premature termination risk at intake could enable targeted clinical responses.Objectives: To develop and externally validate a machine learning model predicting premature treatment termination in OUD; to derive a clinical risk stratification system; and to identify variables most associated with predicted probability.Methods: Retrospective data from the Information System of the Andalusian (South Spain) Plan on Drugs and Addictions (SiPASDA) covered 11,475 patients (86.2% male) admitted to 121 public outpatient centers between 2015 and 2023 (90.8% termination rate). A CatBoost classifier was developed (n = 10,328) and externally validated (n = 1147). Predicted probabilities were discretized into low, moderate- and high‑risk strata. Shapley Additive exPlanations (SHAP) analysis quantified global and stratum-specific predictor contributions.Results: CRIBOOST achieved an area under the receiver operating characteristic curve (AUC-ROC) of 0.652 ± 0.018 in cross-validation and 0.646 externally. Termination rates rose monotonically across strata: 34.6% (low); 69.6% (moderate); 80.8% (high). Housing instability was the strongest positive predictor (SHAP= +0.569; +0.601 in high‑risk). Judicial referral was most protective (SHAP = -0.412), attenuating from low (-0.553) to high (-0.254); employment showed a similar gradient. Mood disorder (SHAP =  +0.470) and benzodiazepine use disorder contributed positively, escalating with risk.Conclusions: CRIBOOST stratifies OUD patients into risk groups at admission using routine intake data, enabling clinicians to target retention-focused interventions where most needed and supporting efficient resource allocation. Stratum-specific SHAP contributions reveal which factors drive risk within each group, informing intervention design.

PMID:
43063324
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement